Nagoya, Japan

Noriyuki Ouchi

This inventor holds 2 USPTO granted patents and 3 published patent applications. Top assignee: Boston University. Active years: 2012-2015.

USPTO Granted Patents = 2 

% Patents Active = 50.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2012-2015

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Noriyuki Ouchi: Innovator in Cardiovascular Research

Introduction

Noriyuki Ouchi is a prominent inventor based in Nagoya, Japan. He has made significant contributions to the field of medical research, particularly in the area of cardiovascular health. With a total of 2 patents, Ouchi's work focuses on innovative methods to treat ischemic injuries.

Latest Patents

Ouchi's latest patents include a method of treating ischemic injury with follistatin-like 1 polypeptide. This invention describes methods and compositions related to the discovery that the Follistatin-like 1 protein (Fstl-1) has metabolic and cardioprotective effects in vivo. Fstl-1, along with its portions, derivatives, or variants, can be utilized to treat or prevent metabolic diseases or disorders and to mitigate cardiac damage caused by interrupted blood supply to cardiac muscle.

Career Highlights

Noriyuki Ouchi is affiliated with Boston University, where he continues to advance his research in the medical field. His work has garnered attention for its potential to improve treatment options for patients suffering from cardiovascular issues.

Collaborations

Ouchi has collaborated with notable researchers, including Kenneth Walsh and Yuichi Oshima. These partnerships have further enhanced the impact of his research and innovations.

Conclusion

Noriyuki Ouchi's contributions to cardiovascular research through his innovative patents highlight his role as a key inventor in the medical field. His work promises to pave the way for new treatments that can significantly improve patient outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…